Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients

Psychoneuroendocrinology. 2006 Sep;31(8):1019-25. doi: 10.1016/j.psyneuen.2006.06.002.

Abstract

Data suggest that both neurotrophic and hypothalamic-pituitary-adrenocortical (HPA) systems are involved in the pathophysiology of depression. The aim of the present study was to investigate whether the non-conservative brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has an impact on HPA axis activity in depressed patients. At admission, the dexamethasone/CRH (DEX/CRH) test was performed in 187 drug-free in-patients suffering from major depression or depressed state of bipolar disorder (DSM-IV criteria). Moreover, genotyping of BDNF Val66Met polymorphism was carried out using the fluorescence resonance energy transfer method (FRET). Homozygous carriers of the Met/Met genotype showed a significantly higher HPA axis activity during the DEX/CRH test than patients carrying the Val/Val or Val/Met genotype (ACTH, cortisol). Our results further contribute to the hypothesized association between HPA axis dysregulation and reduced neuroplasticity in depression and are consistent with the assumption that BDNF is a stress-responsive intercellular messenger modifying HPA axis activity.

MeSH terms

  • Adrenocorticotropic Hormone / blood
  • Adult
  • Amino Acid Substitution
  • Bipolar Disorder / psychology
  • Brain-Derived Neurotrophic Factor / genetics*
  • Corticotropin-Releasing Hormone*
  • Depressive Disorder / genetics*
  • Depressive Disorder / psychology*
  • Depressive Disorder, Major / psychology
  • Dexamethasone*
  • Female
  • Genotype
  • Humans
  • Hydrocortisone / metabolism
  • Hypothalamo-Hypophyseal System / physiology
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Psychiatric Status Rating Scales

Substances

  • Brain-Derived Neurotrophic Factor
  • Dexamethasone
  • Adrenocorticotropic Hormone
  • Corticotropin-Releasing Hormone
  • Hydrocortisone